Luiz Henrique Araujo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luiz Henrique Araujo has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- Clarissa Baldotto
Instituto D’Or de Pesquisa e Ensino - Department of Clinical Oncology , Rio de Janeiro
8 shared publications - Gilberto de Castro
Department of Oncology, Hospital Sirio-Libanes, Sao Paulo, SP, Brazil
7 shared publications - Eldsamira Mascarenhas
Instituto D'Or de ensino e pesquisa, Rio de Janeiro, Brazil
5 shared publications - Vladmir Cláudio Cordeiro de Lima
A.C. Camargo Cancer Center, Sao Paulo, Brazil
5 shared publications Clarissa Mathias
Nucleo de Oncologia da Bahia, Salvador, Brazil
4 shared publicationsMauro Zukin
José Alencar Gomes da Silva Cancer Institute (INCA), São Paulo, Brazil
4 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (16) , e70372
Multidisciplinary Team Care for Early‐Stage Lung Cancer in Low‐ and Middle‐Income Countries and Emerging Economies: Current Position and Call for Action
Lung cancer (LC) is a complex cancer marked by poor prognosis. Low‐ and middle‐income countries (LMICs) and emerging economies have witnessed a growing burden of LC in recent years due to low symptom awareness, rising tobacco use, air pollution, and pulmonary infections. Managing LC optimally requires a multidisciplinary team (MDT) approach to support accurate diagnosis, staging, and treatment. MDT presentation has been linked to timely diagnosis and staging, receipt of surgery, and survival benefits in early‐stage LC (ESLC). However, delivering high‐quality ESLC care through an MDT approach remains challenging in LMICs and emerging economies. Weak organizational structure, fragmentation of the financing and health system, oncology workforce deficits, and unawareness of the potential impact of MDTs hinder optimal care. Systematic identification, analysis, and reporting of barriers to ESLC care are critical for improving care quality and informing effective corrective interventions. This article aimed to explore barriers to MDT implementation that are unique to the care of patients with ESLC in LMICs and emerging economies and developed evidence‐informed recommendations for strengthening MDT care pathways. Key focus areas addressed by these recommendations include the composition of the MDT panel for ESLC management, standardizing MDT processes and guidelines, defining standardized datasets for data collection and internal MDT review, data sharing practices, and streamlining decision‐making processes. This guidance document also provides a rational framework for improved standardized MDT care in ESLC (RISE‐LC) to guide the implementation and optimization of MDT care in resource‐constrained settings, aiming to improve timely diagnosis, treatment coordination, and patient outcomes.
- 18 August 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (16) , e70372
Open AccessMultidisciplinary Team Care for Early‐Stage Lung Cancer in Low‐ and Middle‐Income Countries and Emerging Economies: Current Position and Call for Action
Lung cancer (LC) is a complex cancer marked by poor prognosis. Low‐ and middle‐income countries (LMICs) and emerging economies have witnessed a growing burden of LC in recent years due to low symptom awareness, rising tobacco use, air pollution, and pulmonary infections. Managing LC optimally requires a multidisciplinary team (MDT) approach to support accurate diagnosis, staging, and treatment. MDT presentation has been linked to timely diagnosis and staging, receipt of surgery, and survival benefits in early‐stage LC (ESLC). However, delivering high‐quality ESLC care through an MDT approach remains challenging in LMICs and emerging economies. Weak organizational structure, fragmentation of the financing and health system, oncology workforce deficits, and unawareness of the potential impact of MDTs hinder optimal care. Systematic identification, analysis, and reporting of barriers to ESLC care are critical for improving care quality and informing effective corrective interventions. This article aimed to explore barriers to MDT implementation that are unique to the care of patients with ESLC in LMICs and emerging economies and developed evidence‐informed recommendations for strengthening MDT care pathways. Key focus areas addressed by these recommendations include the composition of the MDT panel for ESLC management, standardizing MDT processes and guidelines, defining standardized datasets for data collection and internal MDT review, data sharing practices, and streamlining decision‐making processes. This guidance document also provides a rational framework for improved standardized MDT care in ESLC (RISE‐LC) to guide the implementation and optimization of MDT care in resource‐constrained settings, aiming to improve timely diagnosis, treatment coordination, and patient outcomes.
- 7 March 2026
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (5) , 112-120.e3
Real-World Evidence of Immunohistochemical Discordance in Breast Cancer Brain Metastases
- 7 March 2026
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (5) , 112-120.e3
Real-World Evidence of Immunohistochemical Discordance in Breast Cancer Brain Metastases
- Open Access
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (3) , e2500066
Systematic Review and Meta-Analysis of Lung Cancer Diagnostic Methods by the Brazilian Thoracic Oncology Group (GBOT)
PURPOSE: Although various techniques are available for diagnosing lung cancer (LC), comprehensive literature synthesis for selecting the most appropriate diagnostic method remains lacking. This study aims to synthesize and meta-analyze the diagnostic accuracy of bronchoscopy and transthoracic needle biopsy (TTNB) in LC diagnosis. METHODS: A systematic review was conducted to evaluate the diagnostic accuracy of bronchoscopy and TTNB for LC diagnosis. MEDLINE/PubMed, EMBASE, Web of Science, Cochrane Library, and LILACS were systematically searched to identify relevant studies. We included original diagnostic accuracy studies with over 50 participants comparing bronchoscopy or TTNB to surgical biopsy or clinical follow-up. Data were synthesized using a bivariate diagnostic accuracy random-effects model, and the quality of evidence was assessed using QUADAS-2. RESULTS: The search identified 3,707 bronchoscopy studies, of which two met inclusion criteria, precluding meta-analysis because of high heterogeneity. For TTNB, 1,136 studies were screened, with 20 included. Meta-analysis of TTNB studies revealed pooled sensitivity and specificity of 0.91 (95% CI, 0.90 to 0.93) and 0.99 (95% CI, 0.98 to 1.00), respectively. Likelihood ratios indicated high post-test probability of accurate diagnosis across clinical scenarios. CONCLUSION: TTNB demonstrates good diagnostic accuracy for peripheral lung lesions, but carries notable complication risks. Bronchoscopy, while less sensitive, remains valuable for central lesions and mediastinal evaluation. These findings underscore the need for a tailored diagnostic approach on the basis of lesion characteristics and patient profiles, complemented by multidisciplinary expertise.
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (3) , e2500066
Open AccessSystematic Review and Meta-Analysis of Lung Cancer Diagnostic Methods by the Brazilian Thoracic Oncology Group (GBOT)
PURPOSE: Although various techniques are available for diagnosing lung cancer (LC), comprehensive literature synthesis for selecting the most appropriate diagnostic method remains lacking. This study aims to synthesize and meta-analyze the diagnostic accuracy of bronchoscopy and transthoracic needle biopsy (TTNB) in LC diagnosis. METHODS: A systematic review was conducted to evaluate the diagnostic accuracy of bronchoscopy and TTNB for LC diagnosis. MEDLINE/PubMed, EMBASE, Web of Science, Cochrane Library, and LILACS were systematically searched to identify relevant studies. We included original diagnostic accuracy studies with over 50 participants comparing bronchoscopy or TTNB to surgical biopsy or clinical follow-up. Data were synthesized using a bivariate diagnostic accuracy random-effects model, and the quality of evidence was assessed using QUADAS-2. RESULTS: The search identified 3,707 bronchoscopy studies, of which two met inclusion criteria, precluding meta-analysis because of high heterogeneity. For TTNB, 1,136 studies were screened, with 20 included. Meta-analysis of TTNB studies revealed pooled sensitivity and specificity of 0.91 (95% CI, 0.90 to 0.93) and 0.99 (95% CI, 0.98 to 1.00), respectively. Likelihood ratios indicated high post-test probability of accurate diagnosis across clinical scenarios. CONCLUSION: TTNB demonstrates good diagnostic accuracy for peripheral lung lesions, but carries notable complication risks. Bronchoscopy, while less sensitive, remains valuable for central lesions and mediastinal evaluation. These findings underscore the need for a tailored diagnostic approach on the basis of lesion characteristics and patient profiles, complemented by multidisciplinary expertise.
- Open Access
- 31 January 2025
- Published by EDIPUCRS in Scientia Medica
- Vol. 35 (1) , e47468
Small cell lung cancer treatment and survival:
Objective: To evaluate the characteristics, treatment received, survival, and prognostic factors of small cell lung cancer patients. Methods: A retrospective cohort study was conducted at the reference a public cancer-center in Rio de Janeiro, Brazil. A total of 866 small cell lung cancer patients admitted in the period 2000-2020 participated in the study. Comparison between survival curves was performed by the log-rank test; variables whose p < 0.10 entered in the Cox regression models expressed as hazard ratios (HR) with 95% confidence intervals. The association between receiving best supportive care (none treatment) and admission period was evaluated by means of logistic regression. Results: Median and 12-months survival were 6.2 and 23.7%, respectively. On multivariate Cox regression adjusted for treatment, poor (HR: 1.99; 1.57-2.51) and unknown performance status (HR: 2.79; 2.22-3.49), non-white skin color (HR: 1.25; 1.07-1.46), extensive (HR: 1.62; 1.29-2.04) and unknown staging (HR: 1.33; 1.07-1.65) remained associated with 12-months survival. Patients admitted during the last three admission period were nearly four times more likely to receive best supportive care in comparison to the first period. Conclusion: The prognosis of small cell lung cancer is poor and the perspective toward increasing their survival is to improve the timely access to diagnosis and treatment.
- 31 January 2025
- Published by EDIPUCRS in Scientia Medica
- Vol. 35 (1) , e47468
Open AccessSmall cell lung cancer treatment and survival:
Objective: To evaluate the characteristics, treatment received, survival, and prognostic factors of small cell lung cancer patients. Methods: A retrospective cohort study was conducted at the reference a public cancer-center in Rio de Janeiro, Brazil. A total of 866 small cell lung cancer patients admitted in the period 2000-2020 participated in the study. Comparison between survival curves was performed by the log-rank test; variables whose p < 0.10 entered in the Cox regression models expressed as hazard ratios (HR) with 95% confidence intervals. The association between receiving best supportive care (none treatment) and admission period was evaluated by means of logistic regression. Results: Median and 12-months survival were 6.2 and 23.7%, respectively. On multivariate Cox regression adjusted for treatment, poor (HR: 1.99; 1.57-2.51) and unknown performance status (HR: 2.79; 2.22-3.49), non-white skin color (HR: 1.25; 1.07-1.46), extensive (HR: 1.62; 1.29-2.04) and unknown staging (HR: 1.33; 1.07-1.65) remained associated with 12-months survival. Patients admitted during the last three admission period were nearly four times more likely to receive best supportive care in comparison to the first period. Conclusion: The prognosis of small cell lung cancer is poor and the perspective toward increasing their survival is to improve the timely access to diagnosis and treatment.
- 20 October 2023
- Published by Elsevier in Annals of Oncology
- Vol. 34, S848
1506TiP A single-arm, phase II study of amivantamab (AMI), lazertinib (L) and pemetrexed (P) for first-line treatment of recurrent/metastatic non-small cell lung cancers (NSCLCS) with epidermal growth factor receptor mutations in Exons 19 or 21 (EGFR 19/21): AMIGO 1 (LACOG0821)
- 20 October 2023
- Published by Elsevier in Annals of Oncology
- Vol. 34, S848
1506TiP A single-arm, phase II study of amivantamab (AMI), lazertinib (L) and pemetrexed (P) for first-line treatment of recurrent/metastatic non-small cell lung cancers (NSCLCS) with epidermal growth factor receptor mutations in Exons 19 or 21 (EGFR 19/21): AMIGO 1 (LACOG0821)
- Open Access
- 1 September 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 9 (9) , e2200426
EGFR Mutation Detection in Brazilian Patients With Non–Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing
PURPOSE: There is a paucity of consistent data concerning genetic mutations in Brazilian patients with lung cancer. The aim of this study was to retrospectively analyze epidermal growth factor receptor (EGFR) mutations detected in a real-world scenario using a large cohort of Brazilian patients with non–small-cell lung cancer (NSCLC). MATERIALS AND METHODS: This was a cross-sectional, observational, descriptive study on the basis of a database of EGFR molecular analysis from tumor samples of patients with a confirmatory histopathological diagnosis of primary lung cancer. Specimens were collected from 2013 to 2017 and were tested using cobas, next-generation sequencing, and Sanger sequencing platforms. RESULTS: A total of 7,413 tumor specimens were tested. The patients were predominantly women with a median age of 67.0 years. Patients with at least one mutation represented 24.2% of the total sample. Among the positive patients, the majority had just one mutation, but two or more simultaneous mutations were observed in 1.52% of patients. Exon 19 deletion was the most prevalent alteration in the sample (12.8%), followed by exon 21 L858R (6.9%) and exon 20 insertion (1.6%). All others were considered uncommon mutations and were observed in 18.5% of all mutated patients and 4.0% of the total sample (2.3%-18.7% depending on the sequencing method). CONCLUSION: This study examined the prevalence of EGFR mutations in Brazilian patients with NSCLC using different technologies, suggesting that the type of method used, directed or nondirected against specific mutations, influences the analysis, particularly for uncommon mutations, which will be missed by mutation-specific approaches such as cobas testing. Our estimates are the largest in Latin America and are consistent with previous reports from other parts of the world. Besides the variability in methods described here as technology incorporation advances in a nonhomogeneous manner, it is probably like the real-world clinical setting Brazilian oncologists face in their daily practice.
- 1 September 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 9 (9) , e2200426
Open AccessEGFR Mutation Detection in Brazilian Patients With Non–Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing
PURPOSE: There is a paucity of consistent data concerning genetic mutations in Brazilian patients with lung cancer. The aim of this study was to retrospectively analyze epidermal growth factor receptor (EGFR) mutations detected in a real-world scenario using a large cohort of Brazilian patients with non–small-cell lung cancer (NSCLC). MATERIALS AND METHODS: This was a cross-sectional, observational, descriptive study on the basis of a database of EGFR molecular analysis from tumor samples of patients with a confirmatory histopathological diagnosis of primary lung cancer. Specimens were collected from 2013 to 2017 and were tested using cobas, next-generation sequencing, and Sanger sequencing platforms. RESULTS: A total of 7,413 tumor specimens were tested. The patients were predominantly women with a median age of 67.0 years. Patients with at least one mutation represented 24.2% of the total sample. Among the positive patients, the majority had just one mutation, but two or more simultaneous mutations were observed in 1.52% of patients. Exon 19 deletion was the most prevalent alteration in the sample (12.8%), followed by exon 21 L858R (6.9%) and exon 20 insertion (1.6%). All others were considered uncommon mutations and were observed in 18.5% of all mutated patients and 4.0% of the total sample (2.3%-18.7% depending on the sequencing method). CONCLUSION: This study examined the prevalence of EGFR mutations in Brazilian patients with NSCLC using different technologies, suggesting that the type of method used, directed or nondirected against specific mutations, influences the analysis, particularly for uncommon mutations, which will be missed by mutation-specific approaches such as cobas testing. Our estimates are the largest in Latin America and are consistent with previous reports from other parts of the world. Besides the variability in methods described here as technology incorporation advances in a nonhomogeneous manner, it is probably like the real-world clinical setting Brazilian oncologists face in their daily practice.
- Top Cited PapersOpen Access
- 20 February 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (6) , 1213-1227
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
PURPOSE: The open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and chemotherapy (T + D + CT) and durvalumab plus chemotherapy (D + CT) versus chemotherapy alone (CT) in first-line metastatic non–small-cell lung cancer (mNSCLC). METHODS: Patients (n = 1,013) with EGFR/ ALK wild-type mNSCLC were randomly assigned (1:1:1) to tremelimumab 75 mg plus durvalumab 1,500 mg and platinum-based chemotherapy for up to four 21-day cycles, followed by durvalumab once every 4 weeks until progression and one additional tremelimumab dose; durvalumab plus chemotherapy for up to four 21-day cycles, followed by durvalumab once every 4 weeks until progression; or chemotherapy for up to six 21-day cycles (with or without maintenance pemetrexed; all arms). Primary end points were progression-free survival (PFS) and overall survival (OS) for D + CT versus CT. Key alpha-controlled secondary end points were PFS and OS for T + D + CT versus CT. RESULTS: PFS was significantly improved with D + CT versus CT (hazard ratio [HR], 0.74; 95% CI, 0.62 to 0.89; P = .0009; median, 5.5 v 4.8 months); a trend for improved OS did not reach statistical significance (HR, 0.86; 95% CI, 0.72 to 1.02; P = .0758; median, 13.3 v 11.7 months; 24-month OS, 29.6% v 22.1%). PFS (HR, 0.72; 95% CI, 0.60 to 0.86; P = .0003; median, 6.2 v 4.8 months) and OS (HR, 0.77; 95% CI, 0.65 to 0.92; P = .0030; median, 14.0 v 11.7 months; 24-month OS, 32.9% v 22.1%) were significantly improved with T + D + CT versus CT. Treatment-related adverse events were maximum grade 3/4 in 51.8%, 44.6%, and 44.4% of patients receiving T + D + CT, D + CT, and CT, respectively; 15.5%, 14.1%, and 9.9%, respectively, discontinued treatment because of treatment-related adverse events. CONCLUSION: D + CT significantly improved PFS versus CT. A limited course of tremelimumab added to durvalumab and chemotherapy significantly improved OS and PFS versus CT, without meaningful additional tolerability burden, representing a potential new option in first-line mNSCLC.
- 20 February 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (6) , 1213-1227
Top Cited PapersOpen AccessDurvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
PURPOSE: The open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and chemotherapy (T + D + CT) and durvalumab plus chemotherapy (D + CT) versus chemotherapy alone (CT) in first-line metastatic non–small-cell lung cancer (mNSCLC). METHODS: Patients (n = 1,013) with EGFR/ ALK wild-type mNSCLC were randomly assigned (1:1:1) to tremelimumab 75 mg plus durvalumab 1,500 mg and platinum-based chemotherapy for up to four 21-day cycles, followed by durvalumab once every 4 weeks until progression and one additional tremelimumab dose; durvalumab plus chemotherapy for up to four 21-day cycles, followed by durvalumab once every 4 weeks until progression; or chemotherapy for up to six 21-day cycles (with or without maintenance pemetrexed; all arms). Primary end points were progression-free survival (PFS) and overall survival (OS) for D + CT versus CT. Key alpha-controlled secondary end points were PFS and OS for T + D + CT versus CT. RESULTS: PFS was significantly improved with D + CT versus CT (hazard ratio [HR], 0.74; 95% CI, 0.62 to 0.89; P = .0009; median, 5.5 v 4.8 months); a trend for improved OS did not reach statistical significance (HR, 0.86; 95% CI, 0.72 to 1.02; P = .0758; median, 13.3 v 11.7 months; 24-month OS, 29.6% v 22.1%). PFS (HR, 0.72; 95% CI, 0.60 to 0.86; P = .0003; median, 6.2 v 4.8 months) and OS (HR, 0.77; 95% CI, 0.65 to 0.92; P = .0030; median, 14.0 v 11.7 months; 24-month OS, 32.9% v 22.1%) were significantly improved with T + D + CT versus CT. Treatment-related adverse events were maximum grade 3/4 in 51.8%, 44.6%, and 44.4% of patients receiving T + D + CT, D + CT, and CT, respectively; 15.5%, 14.1%, and 9.9%, respectively, discontinued treatment because of treatment-related adverse events. CONCLUSION: D + CT significantly improved PFS versus CT. A limited course of tremelimumab added to durvalumab and chemotherapy significantly improved OS and PFS versus CT, without meaningful additional tolerability burden, representing a potential new option in first-line mNSCLC.
- Open Access
- 1 November 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8) , e2200061
Real-World Evidence of Health Outcomes Related to Lung Stereotactic Body Radiation Therapy in Brazil
PURPOSE: Stereotactic body radiation therapy (SBRT) is an effective option for patients with both early-stage and oligometastatic non–small-cell lung cancer (NSCLC). However, data from Latin America are limited. Therefore, the aim of this study was to investigate the real-world outcomes of applying SBRT for lung lesions in a Brazilian institution. METHODS: This study investigated a consecutive cohort of patients treated with SBRT for lung lesions (primary and metastasis). The study primary outcome was local control rates per lesion. Secondary outcomes included progression-free survival (PFS), overall survival (OS), and toxicity. RESULTS: Between 2015 and 2019, a total of 216 patients received SBRT and were included in the study. The median follow-up was 24.5 months (5-70), primary NSCLC corresponded to 70% (n = 151) and nonprimary lung lesions to 30% (n = 65), respectively. Stage I NSCLC represented 56% (85 of 151) of the NSCLC cohort. The average number of fractions and total dose prescribed was 5 (3-10)/59 Gy (50-62 Gy). For stage I NSCLC (all lesions treated with a biologically effective dose [10] > 100 Gy), 2-year local control, OS, and PFS were 93.4%, 81.6%, and 80.7%, respectively. For stage IV lesions, if biologically effective dose (10) > 100 Gy or < 100 Gy, 2-year local control was 95.8/86.4% ( P = .03), 2-year-OS was 81.6/60.5% ( P = .006), and 2-year PFS was 38.9/17.9% ( P = .10). Late toxicity was observed in 16.2% (n = 35) of the total cases. CONCLUSION: Our results indicate that SBRT is effective (high local control and acceptable toxicity) for treating malignant lung lesions in a real-world scenario in Latin America.
- 1 November 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8) , e2200061
Open AccessReal-World Evidence of Health Outcomes Related to Lung Stereotactic Body Radiation Therapy in Brazil
PURPOSE: Stereotactic body radiation therapy (SBRT) is an effective option for patients with both early-stage and oligometastatic non–small-cell lung cancer (NSCLC). However, data from Latin America are limited. Therefore, the aim of this study was to investigate the real-world outcomes of applying SBRT for lung lesions in a Brazilian institution. METHODS: This study investigated a consecutive cohort of patients treated with SBRT for lung lesions (primary and metastasis). The study primary outcome was local control rates per lesion. Secondary outcomes included progression-free survival (PFS), overall survival (OS), and toxicity. RESULTS: Between 2015 and 2019, a total of 216 patients received SBRT and were included in the study. The median follow-up was 24.5 months (5-70), primary NSCLC corresponded to 70% (n = 151) and nonprimary lung lesions to 30% (n = 65), respectively. Stage I NSCLC represented 56% (85 of 151) of the NSCLC cohort. The average number of fractions and total dose prescribed was 5 (3-10)/59 Gy (50-62 Gy). For stage I NSCLC (all lesions treated with a biologically effective dose [10] > 100 Gy), 2-year local control, OS, and PFS were 93.4%, 81.6%, and 80.7%, respectively. For stage IV lesions, if biologically effective dose (10) > 100 Gy or < 100 Gy, 2-year local control was 95.8/86.4% ( P = .03), 2-year-OS was 81.6/60.5% ( P = .006), and 2-year PFS was 38.9/17.9% ( P = .10). Late toxicity was observed in 16.2% (n = 35) of the total cases. CONCLUSION: Our results indicate that SBRT is effective (high local control and acceptable toxicity) for treating malignant lung lesions in a real-world scenario in Latin America.
- Open Access
- 21 September 2022
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 48 (3) , e20210283
Impact of microvascular invasion on 5-year overall survival of resected non-small cell lung cancer
Objectives: Non-small cell lung cancer (NSCLC) is an incidental and aggressive type of cancer. Although curative treatment can be offered, the recurrence rate is relatively high. Identifying factors that have a prognostic impact may guide changes in the staging system and recommendations for adjuvant therapy. The aim of this study was to evaluate the impact of microvascular invasion on the 5-year overall survival (OS) of patients with resected NSCLC treated at a reference cancer center. Methods: This retrospective, observational cohort study included patients diagnosed with early-stage NSCLC (clinical stages I-IIIA), treated with curative-intent surgery at the Brazilian National Cancer Institute between 2010 and 2016. Results: The dataset comprised 91 surgical patients, mostly females and white, with a mean age of 62 years (range between 29-83). Cases were distributed as stages I, II, and III in 55%, 29%, and 16%. Adenocarcinoma was the predominant histological subtype (67%), and microvascular invasion was present in 25% of the patients. The 5-year OS probability was 60% (95% CI, 48.3-68.9). Among all characteristics, advanced stages (p = 0.001) and the presence of microvascular invasion (p< 0.001) were related to a worse 5-year OS. After adjusting for age group and pathological stage, the presence of microvascular invasion was associated with a 4-fold increased risk of death (HR 3.9, 95% CI, 1.9-8.2). Conclusion: The presence of microvascular invasion was an independent factor related to worse survival and, therefore, should be routinely assessed in resected specimens. Keywords: non-small cell lung cancer, thoracic surgery, survival analysis, microvascular invasion.
- 21 September 2022
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 48 (3) , e20210283
Open AccessImpact of microvascular invasion on 5-year overall survival of resected non-small cell lung cancer
Objectives: Non-small cell lung cancer (NSCLC) is an incidental and aggressive type of cancer. Although curative treatment can be offered, the recurrence rate is relatively high. Identifying factors that have a prognostic impact may guide changes in the staging system and recommendations for adjuvant therapy. The aim of this study was to evaluate the impact of microvascular invasion on the 5-year overall survival (OS) of patients with resected NSCLC treated at a reference cancer center. Methods: This retrospective, observational cohort study included patients diagnosed with early-stage NSCLC (clinical stages I-IIIA), treated with curative-intent surgery at the Brazilian National Cancer Institute between 2010 and 2016. Results: The dataset comprised 91 surgical patients, mostly females and white, with a mean age of 62 years (range between 29-83). Cases were distributed as stages I, II, and III in 55%, 29%, and 16%. Adenocarcinoma was the predominant histological subtype (67%), and microvascular invasion was present in 25% of the patients. The 5-year OS probability was 60% (95% CI, 48.3-68.9). Among all characteristics, advanced stages (p = 0.001) and the presence of microvascular invasion (p< 0.001) were related to a worse 5-year OS. After adjusting for age group and pathological stage, the presence of microvascular invasion was associated with a 4-fold increased risk of death (HR 3.9, 95% CI, 1.9-8.2). Conclusion: The presence of microvascular invasion was an independent factor related to worse survival and, therefore, should be routinely assessed in resected specimens. Keywords: non-small cell lung cancer, thoracic surgery, survival analysis, microvascular invasion.
- Open Access
- 25 April 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8) , e2100333
Non–Small-Cell Lung Cancer With CNS Metastasis: Disparities From a Real-World Analysis (GBOT-LACOG 0417)
PURPOSE: Despite the advances in the approach to non–small-cell lung cancer (NSCLC) with CNS metastasis, access to timely diagnosis and treatment may not be optimal in many instances. Our main objective was to describe a cohort of patients with NSCLC with brain metastases from public and private cancer centers, and the differences between patients' presentation, treatment, and outcomes. METHODS: GBOT-LACOG 0417 is a multi-institutional retrospective cohort study of patients diagnosed with NSCLC and CNS metastasis in Brazil. All patients had confirmed diagnosis of NSCLC between January 2010 and December 2015. CNS metastases were identified by imaging. RESULTS: A total of 273 patients were included. Patients treated at public institutions were more often Black or Brown (38.8% v 15.4%), current or former smoker (88.6% v 60.0%), of squamous cell histology (25.0% v 9.1%), EGFR- and ALK-negative (95.9% v 74.9%), and were less frequently assessed by using brain magnetic resonance imaging (38.8% v 83.6%). At public institutions, patients were more often symptomatic (78.1% v 44.6%) and had worse performance status (Eastern Cooperative Oncology Group 2 or higher 61.5% v 10.3%). CNS metastases were larger (median size 25 v 15 mm) and more often surrounded by edema (67.7% v 55.2%) at public institutions. Patients at public institutions were more frequently treated with whole-brain radiation therapy (72.9% v 45.4%) and less frequently with radiosurgery (6.3% v 24.1%). Among patients from private care, median overall survival was 24.2 months (95% CI, 20.0 to 30.6), significantly higher than in public care (median 12.1 months; 95% CI, 6.7 to 13.6; P < .001). CONCLUSION: Our results demonstrate the discrepancy between public and private health care system in the critical setting of patients with CNS metastasis from NSCLC.
- 25 April 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8) , e2100333
Open AccessNon–Small-Cell Lung Cancer With CNS Metastasis: Disparities From a Real-World Analysis (GBOT-LACOG 0417)
PURPOSE: Despite the advances in the approach to non–small-cell lung cancer (NSCLC) with CNS metastasis, access to timely diagnosis and treatment may not be optimal in many instances. Our main objective was to describe a cohort of patients with NSCLC with brain metastases from public and private cancer centers, and the differences between patients' presentation, treatment, and outcomes. METHODS: GBOT-LACOG 0417 is a multi-institutional retrospective cohort study of patients diagnosed with NSCLC and CNS metastasis in Brazil. All patients had confirmed diagnosis of NSCLC between January 2010 and December 2015. CNS metastases were identified by imaging. RESULTS: A total of 273 patients were included. Patients treated at public institutions were more often Black or Brown (38.8% v 15.4%), current or former smoker (88.6% v 60.0%), of squamous cell histology (25.0% v 9.1%), EGFR- and ALK-negative (95.9% v 74.9%), and were less frequently assessed by using brain magnetic resonance imaging (38.8% v 83.6%). At public institutions, patients were more often symptomatic (78.1% v 44.6%) and had worse performance status (Eastern Cooperative Oncology Group 2 or higher 61.5% v 10.3%). CNS metastases were larger (median size 25 v 15 mm) and more often surrounded by edema (67.7% v 55.2%) at public institutions. Patients at public institutions were more frequently treated with whole-brain radiation therapy (72.9% v 45.4%) and less frequently with radiosurgery (6.3% v 24.1%). Among patients from private care, median overall survival was 24.2 months (95% CI, 20.0 to 30.6), significantly higher than in public care (median 12.1 months; 95% CI, 6.7 to 13.6; P < .001). CONCLUSION: Our results demonstrate the discrepancy between public and private health care system in the critical setting of patients with CNS metastasis from NSCLC.